Norinchukin Bank The Buys 4,004 Shares of Danaher Corporation $DHR

Key Points

• Norinchukin Bank increased its stake in Danaher Corporation by 13.3% during the first quarter, holding a total of 34,049 shares valued at approximately $6.98 million.
• Danaher reported an earnings per share (EPS) of $1.80 for the most recent quarter, exceeding analysts' expectations of $1.64 and marking a 3.4% revenue increase year-over-year.
• A majority of analysts rate Danaher stock as a "Moderate Buy", with a consensus target price of approximately $247.61.

Norinchukin Bank The grew its stake in Danaher Corporation (NYSE:DHR - Free Report) by 13.3% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 34,049 shares of the conglomerate's stock after purchasing an additional 4,004 shares during the period. Norinchukin Bank The's holdings in Danaher were worth $6,980,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. CW Advisors LLC grew its position in Danaher by 115.9% in the 1st quarter. CW Advisors LLC now owns 27,524 shares of the conglomerate's stock worth $5,678,000 after purchasing an additional 14,775 shares during the last quarter. Summit Financial LLC grew its position in Danaher by 3.0% in the 1st quarter. Summit Financial LLC now owns 8,527 shares of the conglomerate's stock worth $1,748,000 after purchasing an additional 249 shares during the last quarter. Wormser Freres Gestion grew its position in Danaher by 4.1% in the 1st quarter. Wormser Freres Gestion now owns 5,336 shares of the conglomerate's stock worth $1,101,000 after purchasing an additional 208 shares during the last quarter. Price T Rowe Associates Inc. MD grew its position in Danaher by 3.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 19,592,211 shares of the conglomerate's stock worth $4,016,404,000 after purchasing an additional 612,154 shares during the last quarter. Finally, Candriam S.C.A. lifted its holdings in shares of Danaher by 15.4% during the 1st quarter. Candriam S.C.A. now owns 402,524 shares of the conglomerate's stock worth $84,986,000 after acquiring an additional 53,638 shares during the period. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

DHR has been the subject of a number of analyst reports. UBS Group reduced their price objective on shares of Danaher from $240.00 to $225.00 and set a "buy" rating for the company in a report on Wednesday, July 23rd. Evercore ISI reduced their price objective on shares of Danaher from $230.00 to $226.00 and set an "outperform" rating for the company in a report on Tuesday, July 8th. Guggenheim reaffirmed a "buy" rating and set a $250.00 price objective on shares of Danaher in a report on Wednesday, July 23rd. Barclays reaffirmed an "overweight" rating and set a $225.00 price objective (up from $215.00) on shares of Danaher in a report on Tuesday, June 24th. Finally, Deutsche Bank Aktiengesellschaft reduced their price objective on shares of Danaher from $240.00 to $235.00 in a report on Thursday, June 5th. Seventeen investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. According to data from MarketBeat.com, Danaher presently has a consensus rating of "Moderate Buy" and an average target price of $247.61.

Danaher Price Performance

DHR stock traded down $1.96 during trading on Wednesday, hitting $204.29. 742,600 shares of the stock traded hands, compared to its average volume of 4,184,414. Danaher Corporation has a one year low of $171.00 and a one year high of $279.90. The stock has a market cap of $146.28 billion, a price-to-earnings ratio of 43.50, a P/E/G ratio of 2.90 and a beta of 0.73. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32. The company has a 50 day simple moving average of $201.02 and a 200 day simple moving average of $199.43.

Danaher (NYSE:DHR - Get Free Report) last announced its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, topping analysts' consensus estimates of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The company had revenue of $5.94 billion during the quarter, compared to the consensus estimate of $5.83 billion. During the same period in the previous year, the firm posted $1.72 earnings per share. The company's revenue was up 3.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Equities analysts expect that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Insider Activity at Danaher

In other news, Director Teri List sold 2,778 shares of Danaher stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the sale, the director owned 20,751 shares in the company, valued at $4,379,706.06. The trade was a 11.81% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 11.20% of the stock is currently owned by corporate insiders.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.